Article
Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 15 Oct 2001
Stevenson J P, Redlinger M, Kluijtmans L A, Sun W, Algazy K, Giantonio B, Haller D G, Hardy C, Whitehead A S, O'Dwyer P J
Abstract excerpt
PURPOSE: Irinotecan and raltitrexed display schedule-dependent synergy in vitro, which supports the clinical investigation of the combination. Functional polymorphisms of the methylenetetrahydrofolate reductase (MTHFR) gene result in intracellular redistribution of folate derivatives, which may affect raltitrexed-associated cytotoxicity. PATIENTS AND METHODS: Patients with a range of solid cancers and good...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.